AI Engines For more Details: Perplexity Kagi Labs You
Antifungal Activity: Butenafine hydrochloride is effective against a wide range of fungal pathogens, including dermatophytes, yeasts, and molds. It works by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes, thereby disrupting fungal cell growth and causing cell death.
Treatment of Fungal Skin Infections: Butenafine hydrochloride is indicated for the treatment of various fungal skin infections, including athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). It helps relieve symptoms such as itching, burning, redness, and scaling associated with these infections.
Topical Application: Butenafine hydrochloride is typically available as a topical cream, gel, or solution for external use on the skin. It is applied directly to the affected area, allowing for targeted delivery of the medication to the site of infection.
Broad-Spectrum Activity: Butenafine hydrochloride exhibits broad-spectrum antifungal activity, making it effective against various fungal species, including Trichophyton, Epidermophyton, and Microsporum species, which are common causes of fungal skin infections.
Once-Daily Application: In most cases, butenafine hydrochloride is applied once daily to the affected area for a specified duration as directed by a healthcare professional. This once-daily dosing regimen offers convenience and may improve patient compliance with treatment.
Rapid Relief of Symptoms: Butenafine hydrochloride provides rapid relief of symptoms associated with fungal skin infections. Patients may experience improvement in symptoms within a few days of starting treatment, although complete resolution of the infection may take several weeks.
Low Risk of Resistance: Butenafine hydrochloride has a low risk of inducing fungal resistance compared to some other antifungal agents. This is attributed to its unique mechanism of action and its ability to target multiple stages of fungal cell growth.
Minimal Side Effects: Common side effects associated with butenafine hydrochloride are generally mild and transient. They may include skin irritation, redness, burning, or itching at the site of application. These side effects typically resolve on their own and do not require medical intervention.
Pregnancy and Lactation: The safety of butenafine hydrochloride use during pregnancy and lactation has not been established. Pregnant or breastfeeding individuals should consult their healthcare provider before using this medication.
Avoidance of Contact with Eyes and Mucous Membranes: Butenafine hydrochloride should be kept away from the eyes and mucous membranes, as contact with these areas may cause irritation. If accidental contact occurs, the affected area should be rinsed thoroughly with water.
Complete Course of Treatment: It is important for patients to complete the full course of treatment with butenafine hydrochloride as prescribed by their healthcare provider, even if symptoms improve before the treatment is finished. Failure to complete the course of treatment may result in incomplete resolution of the infection and potential recurrence.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.5 | -0.5 | |
| ADHD | 6.1 | 0.5 | 11.2 |
| Age-Related Macular Degeneration and Glaucoma | 1 | 0.5 | 1 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 2.5 | -0.14 |
| Allergies | 5.4 | 2.5 | 1.16 |
| Allergy to milk products | 1.3 | 1 | 0.3 |
| Alopecia (Hair Loss) | 2.5 | 2.5 | |
| Alzheimer's disease | 2.8 | 7 | -1.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.5 | 0.6 | 4.83 |
| Ankylosing spondylitis | 3.6 | 2.2 | 0.64 |
| Anorexia Nervosa | 0.5 | 3.2 | -5.4 |
| Antiphospholipid syndrome (APS) | 2.2 | 2.2 | |
| Asthma | 1.1 | 0.9 | 0.22 |
| Atherosclerosis | 1.5 | 3 | -1 |
| Atrial fibrillation | 4.8 | 1.3 | 2.69 |
| Autism | 11.3 | 10.8 | 0.05 |
| Barrett esophagus cancer | 0.4 | 0.3 | 0.33 |
| benign prostatic hyperplasia | 0 | 0 | |
| Bipolar Disorder | 1.3 | 1.8 | -0.38 |
| Brain Trauma | 1 | 0.8 | 0.25 |
| Carcinoma | 4 | 3.7 | 0.08 |
| Celiac Disease | 2.4 | 5.1 | -1.13 |
| Cerebral Palsy | 1.7 | 1.8 | -0.06 |
| Chronic Fatigue Syndrome | 5.8 | 9.1 | -0.57 |
| Chronic Kidney Disease | 2.8 | 2.9 | -0.04 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.7 | 1.5 | 0.13 |
| Chronic Urticaria (Hives) | 1.1 | 0.6 | 0.83 |
| Coagulation / Micro clot triggering bacteria | 0.8 | 1.7 | -1.13 |
| Colorectal Cancer | 3.9 | 1.5 | 1.6 |
| Constipation | 1.8 | 1 | 0.8 |
| Coronary artery disease | 2.4 | 1.3 | 0.85 |
| COVID-19 | 12.9 | 17.7 | -0.37 |
| Crohn's Disease | 7.4 | 7.7 | -0.04 |
| cystic fibrosis | 0 | 1.3 | 0 |
| deep vein thrombosis | 0 | 1.2 | 0 |
| Depression | 10.1 | 10.4 | -0.03 |
| Dermatomyositis | 0.3 | 0.5 | -0.67 |
| Eczema | 1.3 | 2.4 | -0.85 |
| Endometriosis | 3 | 1.8 | 0.67 |
| Eosinophilic Esophagitis | 0.4 | -0.4 | |
| Epilepsy | 2.6 | 2.9 | -0.12 |
| Fibromyalgia | 4.2 | 2.6 | 0.62 |
| Functional constipation / chronic idiopathic constipation | 7.1 | 4.4 | 0.61 |
| gallstone disease (gsd) | 2.8 | 1 | 1.8 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 1.2 | 0.5 |
| Generalized anxiety disorder | 1.4 | 2.8 | -1 |
| giant cell arteritis | 0.5 | -0.5 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.5 | -0.5 | |
| Graves' disease | 1.8 | 2 | -0.11 |
| Halitosis | 0.7 | 0.3 | 1.33 |
| Hashimoto's thyroiditis | 3.3 | 0.8 | 3.12 |
| Hidradenitis Suppurativa | 0.3 | 0.4 | -0.33 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 4.3 | 1.5 | 1.87 |
| hypercholesterolemia (High Cholesterol) | 1 | 0.1 | 9 |
| hyperglycemia | 0 | 1.9 | 0 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.5 | 1 |
| hypersomnia | 0.5 | -0.5 | |
| hypertension (High Blood Pressure | 2.6 | 5 | -0.92 |
| Hypothyroidism | 1.5 | -1.5 | |
| Hypoxia | 0.9 | 0.9 | |
| IgA nephropathy (IgAN) | 5.1 | -5.1 | |
| Inflammatory Bowel Disease | 4.5 | 10.7 | -1.38 |
| Insomnia | 1.1 | 1.3 | -0.18 |
| Intelligence | 1.3 | 1.3 | |
| Intracranial aneurysms | 1.8 | 0.5 | 2.6 |
| Irritable Bowel Syndrome | 4.4 | 5 | -0.14 |
| Liver Cirrhosis | 5.3 | 3.9 | 0.36 |
| Long COVID | 10.7 | 12.5 | -0.17 |
| Low bone mineral density | 1.5 | -1.5 | |
| Lung Cancer | 0.7 | 1.5 | -1.14 |
| ME/CFS with IBS | 1.7 | 3.7 | -1.18 |
| ME/CFS without IBS | 1.9 | 3.2 | -0.68 |
| Menopause | 2.9 | 2.9 | |
| Metabolic Syndrome | 8.6 | 9.1 | -0.06 |
| Mood Disorders | 13.4 | 10.5 | 0.28 |
| multiple chemical sensitivity [MCS] | 1.4 | 0.5 | 1.8 |
| Multiple Sclerosis | 5 | 7 | -0.4 |
| Multiple system atrophy (MSA) | 0.4 | 1.4 | -2.5 |
| Neuropathy (all types) | 0.8 | 0 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 7.2 | -2.27 |
| NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
| Obesity | 10.5 | 5.1 | 1.06 |
| obsessive-compulsive disorder | 7.5 | 5.2 | 0.44 |
| Osteoarthritis | 2.7 | 0.5 | 4.4 |
| Osteoporosis | 1.7 | 0.9 | 0.89 |
| pancreatic cancer | 0.7 | 0.7 | |
| Parkinson's Disease | 2.4 | 5 | -1.08 |
| Polycystic ovary syndrome | 3.2 | 2.9 | 0.1 |
| Postural orthostatic tachycardia syndrome | 0.5 | 1 | -1 |
| Premenstrual dysphoric disorder | 1.5 | 0.5 | 2 |
| primary biliary cholangitis | 0.5 | 0.8 | -0.6 |
| Psoriasis | 5 | 2.9 | 0.72 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7 | 4.5 | 0.56 |
| Rosacea | 1.9 | 1 | 0.9 |
| Schizophrenia | 8.4 | 2.9 | 1.9 |
| scoliosis | 0.5 | 1.5 | -2 |
| Sjögren syndrome | 2.8 | 4.1 | -0.46 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 1 | -2.33 |
| Stress / posttraumatic stress disorder | 2.8 | 2.5 | 0.12 |
| Systemic Lupus Erythematosus | 4.3 | 2.9 | 0.48 |
| Tic Disorder | 1.9 | 1.5 | 0.27 |
| Tourette syndrome | 0 | 0.3 | 0 |
| Type 1 Diabetes | 4.4 | 3.7 | 0.19 |
| Type 2 Diabetes | 9.1 | 7.6 | 0.2 |
| Ulcerative colitis | 2.6 | 5.6 | -1.15 |
| Unhealthy Ageing | 6.7 | 2.9 | 1.31 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.